OTCMKTS:ATMS

Artemis Therapeutics Competitors

$0.30
0.00 (0.00 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.30
Now: $0.30
$0.30
50-Day Range
$0.23
MA: $0.32
$0.52
52-Week Range
$0.03
Now: $0.30
$2.00
VolumeN/A
Average Volume6,000 shs
Market Capitalization$1.55 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.38

Competitors

Artemis Therapeutics (OTCMKTS:ATMS) Vs. ESI, WDFC, CBT, OEC, FTK, and ADES

Should you be buying ATMS stock or one of its competitors? Companies in the industry of "miscellaneous chemical products" are considered alternatives and competitors to Artemis Therapeutics, including Element Solutions (ESI), WD-40 (WDFC), Cabot (CBT), Orion Engineered Carbons (OEC), Flotek Industries (FTK), and Advanced Emissions Solutions (ADES).

Artemis Therapeutics (OTCMKTS:ATMS) and Element Solutions (NYSE:ESI) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, valuation and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Artemis Therapeutics and Element Solutions, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Artemis Therapeutics0000N/A
Element Solutions02202.50

Element Solutions has a consensus price target of $15.75, indicating a potential downside of 17.93%. Given Element Solutions' higher probable upside, analysts plainly believe Element Solutions is more favorable than Artemis Therapeutics.

Risk and Volatility

Artemis Therapeutics has a beta of -0.38, meaning that its share price is 138% less volatile than the S&P 500. Comparatively, Element Solutions has a beta of 1.86, meaning that its share price is 86% more volatile than the S&P 500.

Earnings and Valuation

This table compares Artemis Therapeutics and Element Solutions' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Artemis TherapeuticsN/AN/A$-120,000.00N/AN/A
Element Solutions$1.84 billion2.58$92.20 million$0.8821.81

Element Solutions has higher revenue and earnings than Artemis Therapeutics.

Insider & Institutional Ownership

85.1% of Element Solutions shares are owned by institutional investors. 7.5% of Artemis Therapeutics shares are owned by insiders. Comparatively, 13.2% of Element Solutions shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Artemis Therapeutics and Element Solutions' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Artemis TherapeuticsN/AN/A-227.03%
Element Solutions6.78%10.02%5.03%

Summary

Element Solutions beats Artemis Therapeutics on 10 of the 10 factors compared between the two stocks.

WD-40 (NASDAQ:WDFC) and Artemis Therapeutics (OTCMKTS:ATMS) are both consumer staples companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, institutional ownership and profitability.

Analyst Ratings

This is a summary of recent ratings for WD-40 and Artemis Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
WD-4001002.00
Artemis Therapeutics0000N/A

WD-40 currently has a consensus price target of $295.00, indicating a potential upside of 5.33%. Given WD-40's higher possible upside, analysts clearly believe WD-40 is more favorable than Artemis Therapeutics.

Volatility and Risk

WD-40 has a beta of -0.05, meaning that its stock price is 105% less volatile than the S&P 500. Comparatively, Artemis Therapeutics has a beta of -0.38, meaning that its stock price is 138% less volatile than the S&P 500.

Valuation and Earnings

This table compares WD-40 and Artemis Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
WD-40$423.35 million9.06$55.91 million$4.4063.65
Artemis TherapeuticsN/AN/A$-120,000.00N/AN/A

WD-40 has higher revenue and earnings than Artemis Therapeutics.

Insider and Institutional Ownership

90.4% of WD-40 shares are held by institutional investors. 2.1% of WD-40 shares are held by insiders. Comparatively, 7.5% of Artemis Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares WD-40 and Artemis Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
WD-4012.30%33.97%14.82%
Artemis TherapeuticsN/AN/A-227.03%

Summary

WD-40 beats Artemis Therapeutics on 8 of the 9 factors compared between the two stocks.

Cabot (NYSE:CBT) and Artemis Therapeutics (OTCMKTS:ATMS) are both basic materials companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, institutional ownership and profitability.

Analyst Ratings

This is a summary of recent ratings for Cabot and Artemis Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cabot13202.17
Artemis Therapeutics0000N/A

Cabot currently has a consensus price target of $64.1667, indicating a potential upside of 20.70%. Given Cabot's higher possible upside, analysts clearly believe Cabot is more favorable than Artemis Therapeutics.

Volatility and Risk

Cabot has a beta of 1.6, meaning that its stock price is 60% more volatile than the S&P 500. Comparatively, Artemis Therapeutics has a beta of -0.38, meaning that its stock price is 138% less volatile than the S&P 500.

Valuation and Earnings

This table compares Cabot and Artemis Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cabot$2.61 billion1.15$-238,000,000.00$2.0825.56
Artemis TherapeuticsN/AN/A$-120,000.00N/AN/A

Artemis Therapeutics has lower revenue, but higher earnings than Cabot.

Insider and Institutional Ownership

86.2% of Cabot shares are held by institutional investors. 2.1% of Cabot shares are held by insiders. Comparatively, 7.5% of Artemis Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Cabot and Artemis Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cabot-9.10%11.67%3.92%
Artemis TherapeuticsN/AN/A-227.03%

Summary

Cabot beats Artemis Therapeutics on 7 of the 10 factors compared between the two stocks.

Orion Engineered Carbons (NYSE:OEC) and Artemis Therapeutics (OTCMKTS:ATMS) are both small-cap basic materials companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, institutional ownership and profitability.

Profitability

This table compares Orion Engineered Carbons and Artemis Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Orion Engineered Carbons2.47%38.90%4.96%
Artemis TherapeuticsN/AN/A-227.03%

Analyst Ratings

This is a summary of recent ratings for Orion Engineered Carbons and Artemis Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Orion Engineered Carbons10202.33
Artemis Therapeutics0000N/A

Orion Engineered Carbons currently has a consensus price target of $14.3333, indicating a potential downside of 24.36%. Given Orion Engineered Carbons' higher possible upside, analysts clearly believe Orion Engineered Carbons is more favorable than Artemis Therapeutics.

Valuation and Earnings

This table compares Orion Engineered Carbons and Artemis Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Orion Engineered Carbons$1.48 billion0.78$86.92 million$1.8710.13
Artemis TherapeuticsN/AN/A$-120,000.00N/AN/A

Orion Engineered Carbons has higher revenue and earnings than Artemis Therapeutics.

Insider and Institutional Ownership

86.0% of Orion Engineered Carbons shares are held by institutional investors. 1.3% of Orion Engineered Carbons shares are held by insiders. Comparatively, 7.5% of Artemis Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

Orion Engineered Carbons has a beta of 1.76, meaning that its stock price is 76% more volatile than the S&P 500. Comparatively, Artemis Therapeutics has a beta of -0.38, meaning that its stock price is 138% less volatile than the S&P 500.

Summary

Orion Engineered Carbons beats Artemis Therapeutics on 9 of the 10 factors compared between the two stocks.

Flotek Industries (NYSE:FTK) and Artemis Therapeutics (OTCMKTS:ATMS) are both small-cap oils/energy companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, profitability, risk and analyst recommendations.

Profitability

This table compares Flotek Industries and Artemis Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Flotek Industries-261.44%-36.31%-27.10%
Artemis TherapeuticsN/AN/A-227.03%

Analyst Recommendations

This is a summary of recent recommendations and price targets for Flotek Industries and Artemis Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Flotek Industries0000N/A
Artemis Therapeutics0000N/A

Valuation & Earnings

This table compares Flotek Industries and Artemis Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Flotek Industries$119.35 million0.95$-32,280,000.00N/AN/A
Artemis TherapeuticsN/AN/A$-120,000.00N/AN/A

Artemis Therapeutics has lower revenue, but higher earnings than Flotek Industries.

Insider & Institutional Ownership

29.1% of Flotek Industries shares are held by institutional investors. 9.9% of Flotek Industries shares are held by insiders. Comparatively, 7.5% of Artemis Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Flotek Industries has a beta of 2.66, meaning that its share price is 166% more volatile than the S&P 500. Comparatively, Artemis Therapeutics has a beta of -0.38, meaning that its share price is 138% less volatile than the S&P 500.

Summary

Flotek Industries beats Artemis Therapeutics on 5 of the 8 factors compared between the two stocks.

Advanced Emissions Solutions (NASDAQ:ADES) and Artemis Therapeutics (OTCMKTS:ATMS) are both small-cap industrial products companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, profitability, risk and analyst recommendations.

Profitability

This table compares Advanced Emissions Solutions and Artemis Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Advanced Emissions Solutions-19.63%15.49%9.29%
Artemis TherapeuticsN/AN/A-227.03%

Analyst Recommendations

This is a summary of recent recommendations and price targets for Advanced Emissions Solutions and Artemis Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Advanced Emissions Solutions0000N/A
Artemis Therapeutics0000N/A

Valuation & Earnings

This table compares Advanced Emissions Solutions and Artemis Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Advanced Emissions Solutions$70.09 million1.38$35.54 millionN/AN/A
Artemis TherapeuticsN/AN/A$-120,000.00N/AN/A

Advanced Emissions Solutions has higher revenue and earnings than Artemis Therapeutics.

Insider & Institutional Ownership

61.1% of Advanced Emissions Solutions shares are held by institutional investors. 14.9% of Advanced Emissions Solutions shares are held by insiders. Comparatively, 7.5% of Artemis Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Advanced Emissions Solutions has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500. Comparatively, Artemis Therapeutics has a beta of -0.38, meaning that its share price is 138% less volatile than the S&P 500.

Summary

Advanced Emissions Solutions beats Artemis Therapeutics on 7 of the 8 factors compared between the two stocks.


Artemis Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Element Solutions logo
ESI
Element Solutions
1.7$19.19flat$4.74 billion$1.84 billion39.98
WD-40 logo
WDFC
WD-40
1.4$280.07flat$3.83 billion$423.35 million63.65Earnings Announcement
Analyst Report
High Trading Volume
Unusual Options Activity
Analyst Revision
News Coverage
Cabot logo
CBT
Cabot
2.0$53.16flat$3.01 billion$2.61 billion-12.54Analyst Downgrade
Orion Engineered Carbons logo
OEC
Orion Engineered Carbons
1.4$18.95flat$1.15 billion$1.48 billion41.20News Coverage
Flotek Industries logo
FTK
Flotek Industries
0.6$1.56flat$113.18 million$119.35 million-0.61
Advanced Emissions Solutions logo
ADES
Advanced Emissions Solutions
0.9$5.22flat$96.67 million$70.09 million-7.91Analyst Downgrade
News Coverage
Gap Down
PURE Bioscience logo
PURE
PURE Bioscience
0.8$0.70flat$61.06 million$6.92 million35.02Gap Down
Flexible Solutions International logo
FSI
Flexible Solutions International
1.2$3.55flat$43.71 million$27.44 million12.68Analyst Downgrade
VRME
VerifyMe
1.0$4.38flat$32.23 million$250,000.00-4.13News Coverage
HighCom Global Security logo
HCGS
HighCom Global Security
0.5$0.02flat$6.68 million$7.48 million0.00Gap Up
ENCR
Ener-Core
0.5$0.08flat$326,000.00N/A0.00
GlyEco logo
GLYE
GlyEco
0.5$0.13flat$185,000.00$6.46 million0.00
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.